Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab - PubMed
5 days ago
- #Infant Health
- #Vaccination
- #RSV
- Two forms of RSV prevention for infants became available in 2023: maternal RSV vaccine and nirsevimab.
- A cohort study in New York assessed RSV immunization rates during the 2023-2024 and 2024-2025 seasons.
- 66.9% of eligible infants received RSV immunization (29.0% maternal vaccine, 37.9% nirsevimab).
- Immunization coverage increased from 57.6% in 2023-2024 to 75.3% in 2024-2025.
- Infants with public insurance were less likely to receive RSV immunization compared to those with private insurance.
- Disparities in RSV immunization highlight the need for targeted interventions.